Barclays’s Chembio diagnostics, Inc. CEMI Stock Holding History

Barclays’s Portfolio CEMI Stock Details CEMI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,359	Closed	-$6K	–	4994
2021 Q3	$6K	Sell	2,359 -1,898	-45%	-$5.26K	﹤0.01%	4593
2021 Q2	$12K	Sell	4,257 -12,259	-74%	-$42.7K	﹤0.01%	4603
2021 Q1	$58K	Buy	16,516 +10,141	+159%	+$56.5K	﹤0.01%	4172
2020 Q4	$31K	Sell	6,375 -2,597	-29%	-$13.4K	﹤0.01%	4588
2020 Q3	$43K	Sell	8,972 -27,457	-75%	-$130K	﹤0.01%	4678
2020 Q2	$119K	Buy	+36,429	New	+$346K	﹤0.01%	4403
2019 Q4	–	Sell	-106	Closed	–	–	7224
2019 Q3	$0	Buy	+106	New	+$632	﹤0.01%	7515
2018 Q4	–	Sell	-4	Closed	–	–	7799
2018 Q3	$0	Buy	+4	New	+$43	﹤0.01%	7710

Other funds holding CEMI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

EGM

Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Barclays's CEMI Position: Q4 2021 in Review

Barclays sold out of Chembio diagnostics, Inc. (CEMI) in Q4 2021, closing a stake of 2,359 shares — an estimated $6K sold.

Barclays first reported a position in CEMI in Q3 2018 and held it in 8 quarters. The position peaked at $119K in Q2 2020. 43 funds tracked by Wall St. Rank hold CEMI as of Q4 2021.

Barclays reported no remaining Chembio diagnostics, Inc. position as of Q4 2021 after selling out during the quarter.
Barclays sold 2,359 Chembio diagnostics, Inc. shares in Q4 2021, an estimated $6K.
Barclays first reported a position in Chembio diagnostics, Inc. in Q3 2018 and held it in 8 quarters.
Barclays's Chembio diagnostics, Inc. position peaked at $119K in Q2 2020.
43 funds tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.